Voyager Therapeutics Announces Second Quarter 2024 Conference Call and Webcast

Rhea-AI Summary

Voyager Therapeutics (Nasdaq: VYGR), a biotechnology company focused on neurogenetic medicines, has announced its upcoming second quarter 2024 financial results release and conference call. The company will report its Q2 2024 financial and operating results after market close on Tuesday, August 6, 2024. Following this, Voyager will host a conference call and webcast at 4:30 p.m. ET.

Interested participants can register for the telephone conference in advance through a provided link. A live webcast will be available on the Investors section of Voyager's website, with a replay accessible for at least 30 days after the call.

LEXINGTON, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report second quarter 2024 financial and operating results after market close on Tuesday, August 6, 2024. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET.

To participate via telephone and join the call live, please register in advance here: https://register.vevent.com/register/BI796eccb31a2e48c9a71f6c41edd5c510. Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a unique passcode. A live webcast of the call will also be available on the Investors section of the Voyager website at ir.voyagertherapeutics.com, and a replay of the call will be available at the same link approximately two hours after its completion. The replay will be available for at least 30 days following the conclusion of the call.

About Voyager Therapeutics

Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc.; and Sangamo Therapeutics, Inc. For more information, visit www.voyagertherapeutics.com.

Voyager Therapeutics^® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc.

Contacts

Trista Morrison, NACD.DC, tmorrison@vygr.com
Investors: Adam Bero, Ph.D., abero@kendallir.com
Media: Brooke Shenkin, brooke@scientpr.com

FAQ

When will Voyager Therapeutics (VYGR) release its Q2 2024 financial results?

Voyager Therapeutics will release its Q2 2024 financial results after market close on Tuesday, August 6, 2024.

What time is Voyager Therapeutics' (VYGR) Q2 2024 earnings call scheduled for?

Voyager Therapeutics' Q2 2024 earnings call is scheduled for 4:30 p.m. ET on Tuesday, August 6, 2024.

How can investors access Voyager Therapeutics' (VYGR) Q2 2024 earnings call?

Investors can access the call via telephone by registering in advance through a provided link, or listen to a live webcast on the Investors section of Voyager's website.

Will a replay of Voyager Therapeutics' (VYGR) Q2 2024 earnings call be available?

Yes, a replay of the call will be available on Voyager's website for at least 30 days following the conclusion of the call.